CDH2 and lung cancer: It has been shown that the expression of CDH2 may potentially cause mesenchymal phenotype by EMT and the promotion of the survival of lung cancer cells with drug-resistant [145, 146], suggesting that CDH2 is a potential therapy target for anti-cancer cells.